Form 8-K · Current Report · Filed 2025-10-03
Alnylam Pharmaceuticals Enters into a $500M Credit Agreement
Alnylam Pharmaceuticals, Inc. has entered into a Credit Agreement with Bank of America, N.A., as Administrative Agent, to establish a $500 million revolving line of credit facility with a $150 million letter of credit sublimit. The Credit Agreement allows for borrowings at varying interest rates and includes financial covenants such as a Total Net Leverage Ratio and interest coverage ratio. The obligations under the agreement are guaranteed by certain subsidiaries and secured by the Company's assets. The agreement also contains customary affirmative and negative covenants and conditions to borrowing. The Maturity Date is set for September 30, 2030, but it may be earlier under certain conditions related to Springing Maturity Debt.
- Filer
- Alnylam Pharmaceuticals Inc. ALNY · NASDAQ
- Filed
- Accession
- 0001193125-25-230201
- CIK
- 0001178670
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Entry into a Material Definitive Agreement
Creation of a Direct Financial Obligation
Financial Statements and Exhibits
Market reaction
Close before filing
$460.99
Next session
-2.0%
Since filing
-55.4%
Latest close
$205.52
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from ALNY reporting the same item, with the next session's move:
About Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc. is a pioneering biotechnology company dedicated to transforming the lives of patients through RNA interference (RNAi) therapeutics. This scientific approach allows for innovative treatments that can silence genes responsible for certain diseases, offering a unique angle on genetic therapies. Alnylam's primary focus is on developing therapeutics for genetic, cardio-metabolic, hepatic infectious, and central nervous system diseases, contributing to redefining how these conditions are treated. The company's groundbreaking work in RNAi provides a platform for addressing otherwise untreatable or poorly managed medical conditions, positioning it as a leader in the biotechnology sector. With numerous collaborations, partnerships, and a growing pipeline of therapeutics, Alnylam plays a crucial role in advancing modern medicine and contributing to the evolving landscape of genetic therapeutics. Headquartered in Cambridge, Massachusetts, Alnylam underscores the critical intersection of innovation, medicine, and gene science in the financial and pharmaceutical markets.
Never miss another ALNY filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.